Endocrine & Metabolic Disorders
ICON's endocrine and metabolic trial experience, supported by a global team of experts
A multifaceted risk factor:
Addressing obesity's impact across the disease spectrum
Obesity is a growing health concern worldwide, with at least 2.8 million people dying each year because of the disease. Explore the implications of obesity as a risk factor across the disease spectrum, and how this may impact treatment, drug development and clinical trials for obesity.
ICON survey report:
Trends and challenges in obesity research and clinical trials
Explore the ICON survey of global industry professionals currently engaged in obesity-related clinical research. Respondents were from organisations ranging from small biotechs to large pharmaceutical companies, as well as academic organisations. The survey was designed to measure industry opinions on trends and challenges for the sector.
Webinar: Addressing the challenges of Type 2 Diabetes global clinical trials via high quality lab solutions
Join ICON’s expert Dr. Andrew Roche, PhD as he speaks about overcoming challenges when developing Diabetes trials. Addressing these challenges via use of high quality tools is critical to successful completion of a clinical trial.
Webinar: Digital solutions to alleviate NASH clinical trial challenges
Find out more about the ability for digital technologies including magnetic resonance imaging (MRI), magnetic resonance elastography (MRE) and whole slide imaging (WSI) to address NASH clinical trial challenges.
Endocrine and Metabolic Disorders blogs and media contributions
-
Media article: Pharma’s obsession with obesity on rise
ICON expert, Jack Martin shares insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma.
-
Media article: Paediatric clinical trials for obesity treatment
In this article, ICON experts Alan Baldridge and Heather Peterson discuss the prevalence of paediatric obesity and assess clinical trials of its treatments.
-
Media article: Taking Stock of Obesity Drug Development: Trends and challenges facing today’s researchers
In this article, Icon’s Jack Martin discusses the direction obesity drug research is heading, and the challenges faced by researchers.
-
Media article: Advancing Research and Development of Multi-indication and Combination Therapies for Obesity
In this article, ICON's Jack Martin explores the impact of comorbidities on obesity therapeutic development including strategic and innovative approaches to therapeutic development and clinical trials design.
-
Media article: Overcoming challenges in obesity-related clinical trials
Recent advancements in obesity treatments have spotlighted the field for healthcare providers and developers. In this article from Drug Discovery World, ICON experts share insights on the clinical trials landscape for obesity and why patient centricity is key to overcoming common challenges in the sector.
-
Media article: The State of Obesity-Related Clinical Research: A Q&A session with ICON's Simon Bruce
ICON’s, Simon Bruce, Vice President of Internal Medicine and Drug Development Solutions sits down for a Q&A with Pharmaceutical Executive and gives an overview on the obesity survey carried out by ICON in January 2024 and what it suggests about the state of the obesity-related pipeline.
-
Media article: Insight into obesity-related clinical research
In an interview with Contract Pharma, ICON’s Adrienne Stoudenmire and Alan Baldridge discuss current obesity R&D trends, challenges associated with obesity-related clinical research, and opportunities in this sector.
-
Media article: ICON Announces Results from Survey on Obesity-related Clinical Research
This news article, from Applied Clinical Trials, outlines findings from ICON’s recent survey of over 100 industry professionals on their opinions on future research within the therapeutic area of obesity treatment.
-
Media article: ICON Survey Stresses Combo Therapies in Obesity Care
This news piece from The Clinical Trial Vanguard provides an overview of the findings from ICON’s recent survey of professionals engaged in obesity-related clinical research. It outlines that most respondents believe that obesity therapy trials should measure multiple outcomes due to the overlap between obesity and related comorbidities.
-
Media article: Diabesity: Implications for treatment and drug development
In this Journal for Clinical Studies’ article, Simon Bruce and Jack Martin discuss the overlap in pathophysiology and treatment of diabetes and obesity along with considerations for streamlining the clinical development of treatments that have therapeutic promise for both conditions.
-
Media article: Patient Centricity in Insulin Injection: Using Technology to Improve Self-Administration
The following media article will explore how injection technology has made self-administration of insulin easier, and how it will continue to develop into the future.
-
Blog: Diabesity: Overlapping pathophysiology informs multi-indication treatment
As recognition of the overlap between obesity and diabetes has grown, so have efforts to develop treatments that can treat the two conditions in tandem.
-
Blog: Wearables “Put to the Test” in Unique Research Project
The mHealth Grand Tour is an “observational study”, developed to demonstrate how innovative products and technical solutions can help the challenges of managing diabetes.
-
Media article: Liver disease, obesity and the value of treatment
The link between obesity and metabolic-dysfunction associated steatotic liver disease (MASLD), and touches on recent advancements in effective treatments for obesity.
Endocrine & Metabolic Disorders services
ICON is an experienced partner who can assist sponsors in navigating the many challenges of endocrine & metabolic disorders drug development. ICON can help sponsors optimise the clinical trial lifecycle from patient enrolment to payer reimbursement with its customisable solutions and proven strategies. Our highly experienced clinical and therapeutic teams have expertise in conducting trials across a wide range of therapeutic areas including, diabetes, cardiometabolic disorders, gastroenterology, and hepatology.